Advancements in the Management of Gynecological Cancers: ESMO 2024 - Episode 4
Emerging Combinations in Maintenance Therapy for Ovarian Cancer
Panelists discuss how emerging maintenance strategies for advanced/metastatic disease increasingly focus on novel combination approaches, including immunotherapy combinations with PARP inhibitors (rucaparib + nivolumab), anti-angiogenic agents (atezolizumab + bevacizumab), and dual targeted therapy (olaparib + cediranib), with ongoing evaluation of optimal patient selection and sequencing in the treatment paradigm.
Video content above is prompted by the following:
What new maintenance strategies (eg, immunotherapy combination therapy or hormonal maintenance therapy) are being explored for advanced/metastatic disease?
- Rucaparib + nivolumab
- Atezolizumab + bevacizumab
- Olaparib + cediranib
- Where do these fit in the treatment paradigm?
- In which patients may you consider these combination approaches?
Related Content:
